PFE Stock Price Jumps on Announcement of $1.95 Billion Payout From U.S. For COVID-19 Vaccine

PFE Stock Price Jumps on Announcement of $1.95 Billion Payout From U.S. For COVID-19 Vaccine

Pfizer (PFE) just announced the U.S. government will pay $1.95 billion for PFE to produce and deliver 100 million doses of its COVID vaccine once the U.S. declares it’s safe and effective. Under the agreement, the U.S. can acquire an additional 500 million doses from PFE. “Through Operation Warp Speed, we are assembling a portfolio of vaccines […]

This High-Yield Asset Class With Shine With Q2 Earnings

This High-Yield Asset Class With Shine With Q2 Earnings

The 2020 second-quarter earnings season promises to be full of surprises – both positive and negative. Shareholders of stocks in index funds like SPY, DIA, and QQQ may be in for a rougher ride than they’d normally expect. With a large portion of the U.S. economy, including companies in SPY, DIA, and QQQ, shut down […]

OMI Stock Price Jumps on Raised Income Projections

OMI Stock Price Jumps on Raised Income Projections

Owens & Minor (OMI) had been flying under Wall Street’s radar until it preannounced earnings this week.  The medical supplies provider told the market it is essentially doubling its previous adjusted net income guidance. OMI raised projections for net income from $0.50 to $0.60 for the year to between $1.00 and $1.20. OMI said it […]

Trade of the Week: NIO

Trade of the Week: NIO

Electric vehicles have been all the rage lately in the stock and options market. NIO (NIO) has been no exception to this. The company is sometimes called the “Tesla of China” and actually has $1 billion worth of sales already. However, the huge run up in the stock price gave NIO an extremely high valuation, […]

FATE Stock Price Jumps on License Agreement with Baylor College for Rejection-Resistant Cellular Therapies

FATE Stock Price Jumps on License Agreement with Baylor College for Rejection-Resistant Cellular Therapies

Since bottoming out in March 2020, Fate Therapeutics (FATE) has run from a low of $19.91 to a current price of $35.50 with plenty of catalysts. For one, FATE just entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class approach that renders off-the-shelf allogeneic cell products resistant […]